Published in Hum Pathol on June 01, 2005
PVT1 dependence in cancer with MYC copy-number increase. Nature (2014) 2.13
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol (2009) 1.63
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer (2006) 1.58
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet (2014) 1.16
DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein. Mol Cancer (2008) 1.08
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer (2014) 1.01
Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS One (2013) 0.94
Breast cancer genomes--form and function. Curr Opin Genet Dev (2010) 0.85
Expanding the functional role of long noncoding RNAs. Cell Res (2014) 0.82
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation. Cell Rep (2016) 0.76
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. Ger Med Sci (2009) 0.75
Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol (2003) 1.04
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer (2014) 1.00
Comparative study of a single-incision laparoscopic and a conventional laparoscopic appendectomy for the treatment of acute appendicitis. J Korean Soc Coloproctol (2012) 0.95
Analysis of the potent prognostic factors in luminal-type breast cancer. J Breast Cancer (2012) 0.88
Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. J Breast Cancer (2011) 0.84
Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat (2006) 0.83
Survey of the application of the korean clinical practice recommendations on breast cancer treatment: the utility of the korean breast cancer society guidelines. J Breast Cancer (2012) 0.83
The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey. Cancer (2010) 0.83
Accelerated partial breast irradiation using multicatheter brachytherapy for select early-stage breast cancer: local control and toxicity. Radiat Oncol (2010) 0.83
Comparison of Doxorubicin plus docetaxel neoadjuvant chemotherapy with Doxorubicin plus vinorelbine in primary breast cancer. J Breast Cancer (2011) 0.81
Multiproject interdependencies in health systems management: a longitudinal qualitative study. Health Care Manage Rev (2013) 0.78
Dynamic contrast-enhanced MR imaging of VX2 carcinomas after X-irradiation in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. Invest Radiol (2003) 0.77
Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) (2016) 0.75
Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. J Breast Cancer (2011) 0.75
Direct chiral analysis of primary amine drugs in human urine by single drop microextraction in-line coupled to CE. Electrophoresis (2009) 0.75